Current Status of <sup>68</sup>Ga-Pentixafor in Solid Tumours

Current Status of <sup>68</sup>Ga-Pentixafor in Solid Tumours

Chemokine receptor CXCR4 is overexpressed in neoplasms and its expression is related to tumour invasion, metastasis and aggressiveness. <sup>68</sup>Ga-Pentixafor is used to non-invasively image the expression of CXCR4 in tumours and has been widely used in haematological malignancies. R...

Full description

Bibliographic Details
Main Authors:	Bawinile Hadebe, Machaba Michael Sathekge, Colleen Aldous, Mariza Vorster
Format:	Article
Language:	English
Published:	MDPI AG 2022-09-01
Series:	Diagnostics
Subjects:	CXCR4 Pentixafor PET
Online Access:	https://www.mdpi.com/2075-4418/12/9/2135

Similar Items

Chemokine Receptor-4 Targeted PET/CT Imaging with <sup>68</sup>Ga-Pentixafor in Head and Neck Cancer—A Comparison with <sup>18</sup>F-FDG and CXCR4 Immunohistochemistry
by: Bawinile Hadebe, et al.
Published: (2024-06-01)

Imaging Inflammation in Atherosclerosis with CXCR4-Directed [<sup>68</sup>Ga]PentixaFor PET/MRI—Compared with [<sup>18</sup>F]FDG PET/MRI
by: Xia Lu, et al.
Published: (2022-07-01)

Fully-automated production of [68Ga]Ga-PentixaFor on the module Modular Lab-PharmTracer
by: Sarah Spreckelmeyer, et al.
Published: (2020-02-01)

68Ga-pentixafor PET/CT in guiding surgical management of primary aldosteronism
by: Guoyang Zheng, et al.
Published: (2025-03-01)

Automated synthesis and quality control of [68Ga]Ga-PentixaFor using the Gaia/Luna Elysia-Raytest module for CXCR4 PET imaging
by: Thomas Daniel, et al.
Published: (2023-02-01)

<sup>68</sup>Ga-DOTATATE and <sup>68</sup>Ga-Pentixafor PET/CT in a Patient with Castleman Disease of the Retroperitoneum
by: Rui Zuo, et al.
Published: (2024-02-01)

On the automated radiosynthesis of pharmaceutical grade [68Ga]Ga-Pentixafor, its pre-clinical evaluation, clinical application and radiation dosimetry aspects
by: Sreeja Raj Menon, et al.
Published: (2025-02-01)

Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [<sup>68</sup>Ga] Pentixafor Internalization in Neuroendocrine Tumor Cells
by: Alexander Weich, et al.
Published: (2021-02-01)

A comparison of the performance of 68Ga-Pentixafor PET/CT versus adrenal vein sampling for subtype diagnosis in primary aldosteronism
by: Xuan Yin, et al.
Published: (2024-02-01)

<sup>68</sup>Ga-Pentixafor PET/CT May Fail to Detect Recurrent Multiple Myeloma with Extramedullary Disease
by: Qingqing Pan, et al.
Published: (2023-02-01)

Bing–Neel Syndrome and Coexisting Pituitary Macroadenoma in a Patient with Waldenström Macroglobulinemia Revealed by <sup>18</sup>F-FDG and <sup>68</sup>Ga-Pentixafor PET/CT
by: Qingqing Pan, et al.
Published: (2023-04-01)

[<sup>68</sup>Ga]Ga-Pentixafor for PET Imaging of Vascular Expression of CXCR-4 as a Marker of Arterial Inflammation in HIV-Infected Patients: A Comparison with <sup>18</sup>F[FDG] PET Imaging
by: Ismaheel O. Lawal, et al.
Published: (2020-12-01)

The value of targeted CXCR4 18F-AlF-NOTA-pentixafor PET/CT for subtyping primary aldosteronism
by: Yushi Peng, et al.
Published: (2025-02-01)

68Ga-Pentixafor PET/CT for the assessment of therapeutic outcomes following superselective adrenal arterial embolization in patients with primary aldosteronism
by: MengDan Li, et al.
Published: (2025-01-01)

Clinical value of 68Ga-pentixafor PET/CT in patients with primary aldosteronism and bilateral lesions: preliminary results of a single-centre study
by: Rui Zuo, et al.
Published: (2024-07-01)

[<sup>68</sup>Ga]Ga-Pentixafor and Sodium [<sup>18</sup>F]Fluoride PET Can Non-Invasively Identify and Monitor the Dynamics of Orthodontic Tooth Movement in Mouse Model
by: Rogerio B. Craveiro, et al.
Published: (2022-09-01)

On the Optimization of the Protocol for Automated Radiosyntheses of [68Ga]Ga-Pentixafor, [68Ga]Ga-FAPI-4 and [68Ga]Ga-DOTATATE in a Modular-Lab Standard
by: Sreeja Menon, et al.
Published: (2024-07-01)

A Rare Aldosterone-Producing Adenoma Detected by 68Ga-pentixafor PET-CT: A Case Report and Literature Review
by: Yunying Cui, et al.
Published: (2019-11-01)

Imaging findings and clinical relevance of 68Ga-Pentixafor PET in atherosclerosis: a systematic review
by: Min Wang, et al.
Published: (2023-10-01)

Towards a General Method for Using Cyclotron-Produced Ga68 to Manufacture Clinical and Research Ga68 Tracers
by: Ivan E. Wang, et al.
Published: (2024-11-01)

[68Ga] Ga-Pentixafor diffuse bilateral Adrenal & Breast uptake in a patient with High-grade Glioma: A note of caution on normal variants
by: Hessamoddin Roustaei, et al.
Published: (2023-06-01)

CXCR4-Directed Imaging in Solid Tumors
by: Rudolf A. Werner, et al.
Published: (2019-08-01)

A Comparison of <sup>68</sup>Ga-PSMA PET/CT-Based Split Renal Function with <sup>99m</sup>Tc-MAG3 Renography in Patients with Metastatic Castration-Resistant Prostate Carcinoma Treated with <sup>177</sup>Lu-PSMA
by: Lerato Gabela, et al.
Published: (2024-03-01)

Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)
by: Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, et al.
Published: (2022-11-01)

A dataset of [68Ga]Ga-Pentixafor PET/CT images of patients with high-grade Glioma
by: Hessamoddin Roustaei, et al.
Published: (2023-06-01)

Semiquantitative Analysis of Physiological Biodistribution of <sup>68</sup>Ga-DOTATATE and <sup>68</sup>Ga-DOTANOC
by: Evrim SÜRER BUDAK, et al.
Published: (2023-07-01)

Automated GMP Production and Preclinical Evaluation of [<sup>68</sup>Ga]Ga-TEoS-DAZA and [<sup>68</sup>Ga]Ga-TMoS-DAZA
by: Julia Greiser, et al.
Published: (2022-12-01)

[<sup>68</sup>Ga]Ga-PSMA and [<sup>68</sup>Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration
by: Samuele Ghezzo, et al.
Published: (2023-08-01)

Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease
by: Dineo Mpanya, et al.
Published: (2023-07-01)

[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01)

<sup>68</sup>Ga-PSMA-11 PET/CT Initial Staging in Black and White South African Males with ISUP Grade Group 1 and 2 Prostate Adenocarcinoma
by: Letjie C. Maserumule, et al.
Published: (2022-04-01)

Role of Combined <sup>68</sup>Ga DOTA-Peptides and <sup>18</sup>F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
by: Chalermrat Kaewput, et al.
Published: (2022-01-01)

68Ga‐nitroimidazole PET/CT imaging of hypoxia in tuberculosis: A case series
by: Philippa L Bresser, et al.
Published: (2022-12-01)

Evaluation of <sup>68</sup>Ga-Radiolabeled Peptides for HER2 PET Imaging
by: Maxwell Ducharme, et al.
Published: (2022-11-01)

Automated Production of [<sup>68</sup>Ga]Ga-Desferrioxamine B on Two Different Synthesis Platforms
by: Martin Kraihammer, et al.
Published: (2024-09-01)

The Role of PET/CT in Breast Cancer
by: Bawinile Hadebe, et al.
Published: (2023-02-01)

Active Lumbar Spondylodiscitis on [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Mimicking Bone Metastasis
by: Florian Rosar, et al.
Published: (2023-12-01)

<sup>68</sup>Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of [<sup>68</sup>Ga]Ga-RM2
by: Adrien Chastel, et al.
Published: (2021-07-01)

Prostate Cancer Biochemical Recurrence Resulted Negative on [<sup>68</sup>Ga]Ga-PSMA-11 but Positive on [<sup>18</sup>F]Fluoromethylcholine PET/CT
by: Riccardo Laudicella, et al.
Published: (2022-09-01)

The Value of <sup>68</sup>Ga-PSMA PET/CT Following Equivocal <sup>18</sup>F-NaF PET/CT in Prostate Cancer Patients
by: Claus Madsen, et al.
Published: (2020-05-01)